GLP-1 Ozempic Semaglutide Tirzepatide Compounding Legal Updates скачать в хорошем качестве

GLP-1 Ozempic Semaglutide Tirzepatide Compounding Legal Updates

📢 GLP-1 Medications – April 2025 Legal Update from Lengea Law 🚨 If your wellness clinic or med spa is offering (or planning to offer) GLP-1 medications like Ozempic, Wegovy, Mounjaro, or compounded semaglutide/tirzepatide, this legal update is a must-watch. The regulatory landscape is changing fast, and staying compliant is critical. In this video, we break down everything you need to know from a legal and compliance perspective. 🔍 What You’ll Learn: • 🆕 Recent FDA Actions & Legal Developments • ⚖️ Current Legal Status of Compounded GLP-1s • 📄 Consent & Disclosure Requirements • 👩‍⚕️ Scope of Practice: Who Can Prescribe & Administer • 🚫 Legal Risks of Off-Label Marketing & Delegation • ✅ How to Stay Compliant in 2025 and Beyond 💬 Have legal questions about offering GLP-1s in your practice? Visit us at LengeaLaw.com or send us a message to schedule a compliance consultation. 📅 Follow for more updates on medical spa regulations, healthcare law, and aesthetic compliance. #GLP1 #Ozempic #Wegovy #Mounjaro #Semaglutide #Tirzepatide #CompoundingLaw #HealthcareCompliance #MedSpaLaw #LengeaLaw #WellnessClinic #MedicalAesthetics #FDARegulations #LegalUpdate